Exelixis (EXEL) EBT Growth (1y) (2011 - 2026)

Exelixis (EXEL) EBT Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 8.48%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.60%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 88.57%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 213.87%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 76.48%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -12.04%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 530.43%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 96.45%
10 Exelixis 12.75 Bn 11.91 Bn 608.03 Mn 14.00%

Historic Data

Download Data
DateValue
Jul 3, 2026 14.00%
Apr 3, 2026 30.14%
Jan 2, 2026 36.76%
Oct 3, 2025 63.10%
Jul 4, 2025 -21.32%
Apr 4, 2025 317.50%
Jan 3, 2025 79.32%
Sep 27, 2024 2,559.93%
Jun 28, 2024 191.72%
Mar 29, 2024 2.05%
Dec 29, 2023 427.87%
Sep 29, 2023 -93.68%
Jun 30, 2023 13.42%
Mar 31, 2023 -43.35%
Dec 30, 2022 -126.63%
Sep 30, 2022 72.82%
Jul 1, 2022 -29.13%
Apr 1, 2022 4,329.73%
Dec 31, 2021 164.75%
Oct 1, 2021 240.08%